ES2174132T3 - N-acil-a,omp-alquil-hidrazino-carboximidamidas. - Google Patents

N-acil-a,omp-alquil-hidrazino-carboximidamidas.

Info

Publication number
ES2174132T3
ES2174132T3 ES96945113T ES96945113T ES2174132T3 ES 2174132 T3 ES2174132 T3 ES 2174132T3 ES 96945113 T ES96945113 T ES 96945113T ES 96945113 T ES96945113 T ES 96945113T ES 2174132 T3 ES2174132 T3 ES 2174132T3
Authority
ES
Spain
Prior art keywords
carbon atoms
composition
group containing
inhibiting
hidrazino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96945113T
Other languages
English (en)
Inventor
Peter C Ulrich
Dilip R Wagle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synvista Therapeutics Inc
Original Assignee
Alteon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/771,959 external-priority patent/US5877217A/en
Application filed by Alteon Inc filed Critical Alteon Inc
Application granted granted Critical
Publication of ES2174132T3 publication Critical patent/ES2174132T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES Y METODOS QUE INHIBEN LA RETICULACION NO ENZIMATICA (ENVEJECIMIENTO DE PROTEINAS) UTILIZANDO COMPUESTOS DE FORMULA (I), DONDE ALK ES UN GRUPO ALQUILENO DE CADENA LINEAL O RAMIFICADA QUE CONTIENE ENTRE 2 Y 8 ATOMOS DE CARBONO, Y R ES UN GRUPO ALQUILO INFERIOR QUE CONTIENE ENTRE 1 Y 6 ATOMOS DE CARBONO; ASI COMO SUS SALES DE ADICION BIOLOGICA O FARMACEUTICAMENTE ACEPTABLES. CONSECUENTEMENTE, SE DESCRIBE UNA COMPOSICION QUE COMPRENDE DICHAS N ACILAMINOALQUILHIDRAZINCARBOXIMIDAMIDAS, QUE SON CAPACES DE INHIBIR LA FORMACION DE PRODUCTOS FINALES DE GLICOSILACION AVANZADA DE PROTEINAS DIANA. DICHO METODO CONSISTE EN PONER EN CONTACTO LA PROTEINA DIANA CON DICHA COMPOSICION. SE PREVEN APLICACIONES TANTO INDUSTRIALES COMO TERAPEUTICAS PARA LA INVENCION, COMO EL TRATAMIENTO DE LA DEGRADACION DE ALIMENTOS Y EL ENVEJECIMIENTO DE PROTEINAS ANIMALES.
ES96945113T 1995-12-26 1996-12-26 N-acil-a,omp-alquil-hidrazino-carboximidamidas. Expired - Lifetime ES2174132T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US922095P 1995-12-26 1995-12-26
US61840796A 1996-03-19 1996-03-19
US08/771,959 US5877217A (en) 1995-12-26 1996-12-23 N-acylaminoalkyl-hydrazinecarboximidamides

Publications (1)

Publication Number Publication Date
ES2174132T3 true ES2174132T3 (es) 2002-11-01

Family

ID=27358809

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96945113T Expired - Lifetime ES2174132T3 (es) 1995-12-26 1996-12-26 N-acil-a,omp-alquil-hidrazino-carboximidamidas.

Country Status (15)

Country Link
EP (1) EP0888293B1 (es)
JP (1) JP2000502684A (es)
CN (1) CN1209117A (es)
AT (1) ATE215068T1 (es)
AU (1) AU720796B2 (es)
BR (1) BR9612304A (es)
CA (1) CA2241746A1 (es)
DE (1) DE69620253T2 (es)
DK (1) DK0888293T3 (es)
ES (1) ES2174132T3 (es)
NO (1) NO982976L (es)
NZ (1) NZ326238A (es)
PT (1) PT888293E (es)
TW (1) TW502012B (es)
WO (1) WO1997023447A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging

Also Published As

Publication number Publication date
EP0888293A1 (en) 1999-01-07
TW502012B (en) 2002-09-11
NO982976L (no) 1998-08-26
DE69620253D1 (en) 2002-05-02
AU1356097A (en) 1997-07-17
DK0888293T3 (da) 2002-04-22
PT888293E (pt) 2002-07-31
BR9612304A (pt) 1999-07-13
NZ326238A (en) 1999-11-29
CA2241746A1 (en) 1997-07-03
EP0888293B1 (en) 2002-03-27
NO982976D0 (no) 1998-06-26
DE69620253T2 (de) 2002-09-19
WO1997023447A1 (en) 1997-07-03
JP2000502684A (ja) 2000-03-07
ATE215068T1 (de) 2002-04-15
AU720796B2 (en) 2000-06-15
CN1209117A (zh) 1999-02-24

Similar Documents

Publication Publication Date Title
ES2174132T3 (es) N-acil-a,omp-alquil-hidrazino-carboximidamidas.
ATE112165T1 (de) Verfahren und mittel zur hemmung des proteinveraltens.
WO1993014750A3 (en) Amino acids useful as inhibitors of the advanced glycosylation of proteins
RU94046295A (ru) L-аспартил-d- альфа -аминоалканоил-(s)-n-d-алкилбензиламиды, используемые в качестве искусственных подслащивающих агентов, пищевой состав, способ подслащивания пищевого состава
NZ312840A (en) Ketoheterocyclic inhibitors of factor Xa
RU94046457A (ru) Производные аспартама, способ их получения и содержащее их подслащивающее средство
HK1039488A1 (en) Tricylic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases.
PT1004578E (pt) Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
MY135057A (en) Dolastatin 15 derivatives
EA199800378A1 (ru) Новый способ получения фенилимидазолидиновых производных
AU3895689A (en) Cyclic sulfur-containing amino acid derivatives
ATE231845T1 (de) 1,2,4-triazinderivate zur inhibierung der proteinglycosylierung
WO1997042175B1 (en) Substituted imidazolium salts and their use for the inhibition of protein ageing
DE69715218T2 (de) Substituierte imidazoliunsalze und deren verwendung zur hemmung der proteinalterung
AU686104B2 (en) Substituted amidinonaphthyl ester derivatives
BR8303032A (pt) Sililoxialcano-azois, processo para sua preparacao, composicoes praguicidas, processo para o combate ou protecao de uma infestacao por microorganismo e processo para a preparacao de uma composicao
DK0835265T3 (da) Blodpladeaggregeringsinhibitorer indeholdende C-terminale aminosyrerester med aminerge sidekæder
DE69622393T2 (de) Neue verwendung von pyrazolopyridinverbindungen
RU94035756A (ru) Производные имидазола, являющиеся ингибиторами питокинов, способы их получения, фармацевтическая композиция

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 888293

Country of ref document: ES